Although CD8+T cells or myeloid CD11b+ or CD11c+ cells did not show any noticeable increase in the intracellular production of IL-2 in the presence of bortezomib administration in 4T1HA tumor-bearing mice (data not shown), we observed a significant increase in the lymphoid CD4+T cells producing higher levels of IL-2 in bortezomib-treated mice (Figure 6A). This evidence concerns the gene ITGAX and neoplasm.